Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORL-1-23 in advanced solid tumors
NCT05103683Phase 1Recruiting
- Sponsor
- TORL BioTherapeutics
- Start
- Nov 2021
- Primary completion
- Aug 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of ixotatug vedotin in solid tumor (advanced stage), ovarian cancer, endometrial cancer (EC) and 1 more, sponsored by TORL BioTherapeutics. Primary endpoints: Incidence and severity of adverse events and serious adverse events at 2 years, Maximum Tolerated Dose at 28 days and 1 more. Started Nov 2021; status: recruiting.
02
Drugs
ixotatug vedotin
03
Conditions
solid tumor (advanced stage)ovarian cancerendometrial cancer (EC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05103683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05103683.